Electra Therapeutics filed for an initial public offering.
The late clinical-stage biopharmaceutical company did not say how many shares it intends to list, or at what price, according to a Friday filing with the Securities and Exchange Commission.
The company focuses on treatments for immune-mediated diseases and cancer. Its lead product candidate, ipsoprubart, is currently in a registrational program to treat secondary hemophagocytic lymphohistiocytosis, according to the filing.
Electra said it would use proceeds from the IPO to advance ipsoprubart and support the development of other possible treatments.
The company said it applied to list its shares on the Nasdaq Global Select Market under the symbol ETRA.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments